@Article{Oncologie.2021.015828,
AUTHOR = {Chunya Hu, Yu He},
TITLE = {Formononetin Inhibits Non-Small Cell Lung Cancer Proliferation via Regulation of mir-27a-3p through p53 Pathway},
JOURNAL = {Oncologie},
VOLUME = {23},
YEAR = {2021},
NUMBER = {2},
PAGES = {241--250},
URL = {http://www.techscience.com/oncologie/v23n2/42964},
ISSN = {1765-2839},
ABSTRACT = {<b>Objective:</b> The aim of the present study was to investigate the anti-tumor effects of formononetin on human nonsmall cell lung cancer (NSCLC) and its potential molecular mechanism. <b>Methods:</b> A549 cells were treated with
different concentrations of formononetin, then detected the cell proliferation, apoptosis and the expression of
HIPK2 respectively by MTT assay, flow cytometry analysis and RT-qPCR. Then the interaction between miR-
27a-3p and its target gene HIPK2 was verified through luciferase reporter assay. The expression of miR-27a-
3p, HIPK2, and p53 was detected after being treated with different formononetin concentrations by RT-qPCR
and western blot. <b>Results:</b> The results showed that formononetin significantly inhibited the proliferation and
induced the apoptosis of A549 cells in a time- and dose-dependent manner. miR-27a-3p targeted HIPK2
3’UTR and inhibited the expression of HIPK2. Also, formononetin-treated A549 cells were remarked with a
significant decline in the expression of miR-27a-3p, accompanied with growth of HIPK2, and subsequently a
reduction of p53. <b>Conclusions:</b> The study indicates that miR-27a-3p might pose regulated effects on the
HIPK2/p53 pathway, resulting in formononetin’s anti-carcinogenic effects on NSCLC <i>in vitro</i>.},
DOI = {10.32604/Oncologie.2021.015828}
}